Evidence map›Paper›PMID 41474325›Full record

ArticlemBio2026

Reprogramming

Victoria Chevée, Mariya Lobanovska, Rafael Rivera-Lugo, Leslie Güereca, Ying Feng, Andrea Anaya-Sanchez, Jesse Garcia Castillo, Austin M Huckins, Edward E Lemmens, Chris S Rae and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07573111 (An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07573111 phase1recruitingnot on this map

An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor (TCR) αβ+ T Cell/CD-19+ B Cell-Depleted Hematopoietic Stem Cell Transplantation

TypeinterventionalSponsorLaguna Biotherapeutics, Inc.Ran2026 to 2029Enrolled12ConditionsAcute Leukemia, Myelodysplastic SyndromeArmsQUAIL-100
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Avoidance of MAIT cells is an essential determinant ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Victoria Chevée *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
Mariya Lobanovska *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.ORCID 0000-0002-3513-301X
Rafael Rivera-Lugo *Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
Leslie GüerecaDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
Ying FengDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
Andrea Anaya-SanchezDepartment of Plant and Microbial Biology, University of California Berkeley, Berkeley, California, USA.
Jesse Garcia CastilloDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
Austin M HuckinsDepartment of Microbiology, Genetics, & Immunology, Michigan State University, East Lansing, Michigan, USA.
Edward E LemmensLaguna Biotherapeutics, San Francisco, California, USA.
Chris S RaeLaguna Biotherapeutics, San Francisco, California, USA.
Jonathan W HardyDepartment of Microbiology, Genetics, & Immunology, Michigan State University, East Lansing, Michigan, USA.ORCID 0000-0001-7686-9819
Russell CarringtonLaguna Biotherapeutics, San Francisco, California, USA.
Jonathan W KotulaLaguna Biotherapeutics, San Francisco, California, USA.
Daniel A PortnoyDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.ORCID 0000-0003-1218-2799

Funding

The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5M
Listeria Hemolysis and Escape From a VacuoleR01AI027655 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DANIEL A PORTNOY · 1993 to 2026
$10.1M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Reversing cancer immunosuppression using attenuated Listeria monocytogenesR01CA283604 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Michel DuPage, DANIEL A PORTNOY · 2024 to 2026
$1.4M
NCI NIH HHS R01 CA283604NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI027655NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FlavinsListeria monocytogenesLymphocyte ActivationT-LymphocytesAnimalsCancer VaccinesFemaleFlavin-Adenine DinucleotideImmunity, InnateListeriosisMiceMice, Inbred C57BLVaccines, AttenuatedCancer VaccinesFlavin-Adenine DinucleotideFlavinsVaccines, AttenuatedflavinsimmunotherapeuticsListeria monocytogenesMAIT cellsvaccines

Identifiers

PMID41474325
PMCPMC12892937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.